Research effects
CJC-1295 NO DAC (without Drug Affinity Complex, i.e., Mod GRF 1-29) is a growth hormone-releasing hormone (GHRH) analogue that promotes pulsatile endogenous growth hormone (GH) secretion.
Catalogue
Research peptides1 specification
CJC-1295 NO(without) DAC
COA on requestThis entry is a lower-strength supplier label for CJC-1295 without DAC, a synthetic GHRH analogue lacking the Drug Affinity Complex modification. It is retained separately pending catalogue normalization.
Wholesale quote requiredPrice confirmed by sales
No payment is taken online. Sales confirms availability, documentation, shipping, and commercial terms.
Purity≥98%Estimated delivery: within one week after the order is placed.
COA is available on request
COA files are available in the document library; additional batch-specific documentation can be requested with your inquiry. Each batch is tested with HPLC purity analysis (≥98%). For MSDS or detailed storage protocols, please contact our sales team.
Order formatOne box accepted
DeliveryWithin one week after order
ShippingShipping and duties included
DocumentationCOA available on request
Efficacy
Users commonly report increased muscle strength, reduced body fat, improved sleep quality, and enhanced skin elasticity. Compared to the DAC-containing version, the NO DAC version has a shorter half-life (approximately 30 minutes), more closely mimicking the physiological pulsatile rhythm of GH secretion. This helps maintain IGF-1 levels within an optimal range and reduces the risk of glucose metabolic disturbances associated with persistently elevated GH. Preclinical studies have confirmed its ability to effectively elevate GH levels without significantly raising prolactin or cortisol, demonstrating favorable selectivity.
Research mechanism
CJC-1295 NO DAC acts by binding to GHRH receptors on the anterior pituitary, activating the adenylyl cyclase/cAMP/PKA signaling pathway to stimulate GH synthesis and release. Specific amino acid modifications in its sequence (including D-isomer substitution at the N-terminal tyrosine and C-terminal amidation) confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, significantly extending its in vivo activity window (approximately 30 minutes). The short-acting nature of the NO DAC version ensures GH release occurs in pulses rather than sustained plateau-like elevations, a feature essential for maintaining normal GH-IGF-1 axis feedback regulation. This effectively avoids insulin resistance and excessive IGF-1 elevation associated with persistently high GH levels, thereby better preserving glucose metabolic balance while enhancing anabolic signaling.
Product details
Key identity and handling information for the selected research material.
Material identity
This name overlaps with the main CJC-1295 No DAC family. Confirm whether both records share the same sequence before merging or quoting.
Storage guidance
Store unopened material in its original sealed packaging, protected from light, moisture, and repeated temperature changes. Follow the product label and batch document for the exact storage temperature. After opening or preparation, use only a validated laboratory storage protocol.
Quality review
Report a quality concern within 14 days of delivery with the order, batch details and available photos.
Resolution
When a quality claim is approved, choose a full refund or replacement shipment.
24/7 WhatsApp contact
Sales support remains available for product, documentation and wholesale inquiry follow-up.
